immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Company profile
Ticker
IMMP
Exchange
Website
CEO
Marc Voigt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Prima BioMed Ltd
SEC CIK
Corporate docs
IMMP stock data
Latest filings (excl ownership)
6-K
Immutep Appoints Leading Research Institute to Conduct
18 Apr 24
6-K
Immutep Announces First Clinical Data from 90mg Dosing of Efti
6 Mar 24
6-K
Half-Year Financial Report
29 Feb 24
6-K
Immutep Quarterly Activities Report & Appendix 4C
30 Jan 24
6-K
Immutep Receives Constructive Regulatory Feedback on TACTI-004
21 Dec 23
6-K
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
7 Dec 23
6-K
Current report (foreign)
9 Nov 23
6-K
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
6 Nov 23
6-K
Immutep Announces New Biomarker Data from TACTI-002 Phase II
3 Nov 23
6-K
Immutep Quarterly Activities Report & Appendix 4C
31 Oct 23
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
1.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 7 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 3.63 bn |
Total shares | 1.91 mm |
Total puts | 161.20 k |
Total calls | 35.40 k |
Total put/call ratio | 4.6 |
Largest owners | Shares | Value |
---|---|---|
Millennium Management | 786.61 k | $1.49 bn |
Oracle Investment Management | 516.43 k | $981.22 mm |
Meridian Wealth Management | 311.20 k | $591.28 mm |
Susquehanna International | 87.76 k | $166.74 mm |
Dimensional Fund Advisors | 70.01 k | $133.01 mm |
Verition Fund Management | 30.00 k | $57.00 mm |
BNP Paribas Arbitrage | 23.94 k | $45.48 mm |
MS Morgan Stanley | 22.79 k | $43.31 mm |
Geode Capital Management | 18.72 k | $35.57 mm |
Integrated Advisors Network | 13.00 k | $24.70 mm |
News
Immutep Appoints Leading Research Institute To Conduct First-in-Human Phase I Study Of IMP761
18 Apr 24
Immutep Announced Tuesday, Positive Feedback From Spanish Medicines Agency For Upcoming TACTI-004 Registrational Trial In Metastatic Non-Small Cell Lung Cancer
17 Apr 24
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
5 Mar 24
Immutep Announces First Clinical Data From 90mg Dosing Of Efti
5 Mar 24